Retinoblastoma Clinical Trial
Official title:
A Phase II Trial of Proton Beam Radiation Therapy for Intra- and Periocular Retinoblastoma
The purpose of this trial is to evaluate proton beam radiation therapy as an alternative to external photon beam irradiation in children with retinoblastoma as a means of local tumor control and ocular retention.
External photon beam radiation therapy (which is current standard of care) has been used in
the treatment of retinoblastoma. It is a form of radiation therapy in which the radiation is
delivered by a machine pointed at the area to be radiated.
Proton beam radiation therapy is a form of external photon beam radiation therapy, but it
may be more effective because its adjusted dosing delivers less radiation to surrounding
areas of the tumor, which helps preserve other tissues and cause fewer side effects.
Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. Your eye doctor will perform an assessment of your eye, including an exam while you
are under anesthesia. This exam will include a dilated eye exam, photography of your
affected eye (by a Ret-Cam), ultrasound of your affected eye, and imaging scans, such as
computed tomography (CT) or magnetic resonance imaging (MRI), if the doctor thinks it is
necessary. The assessments will be done to check and confirm the status of the disease.
After diagnosis of retinoblastoma, the study doctor will first see if external photon beam
radiation therapy is a reasonable treatment option for you. If external photon beam
radiotherapy is deemed appropriate for you, you will be eligible to receive proton beam
radiation therapy in this study.
If you are found to be eligible to take part in this study, you will be treated with proton
beam radiation therapy. Treatment will begin within 1 week of referral to the M. D. Anderson
Proton Center. It will be given daily for 5 days in a row each week (except for Saturdays,
Sundays, and holidays). The whole treatment will take about 4-6 weeks.
Within 2-4 weeks after completion of therapy, you will have an eye exam performed under
anesthesia (like the one during screening). You will have repeated eye exams under
anesthesia, depending on the appearance and response of the tumor to therapy. This will
occur about every 1-4 months.
You will continue to have these eye exams until the tumors are considered to be stable or
unless your disease gets worse.
If the disease gets worse or you experience any intolerable side effects, you may be taken
off treatment.
You will be required to have lifelong eye and medical assessments to continue to monitor you
for disease. If no disease is found 5 years after completion of proton beam radiation
therapy, you will be considered free of disease. You will then have annual (yearly) eye and
pediatric assessment through adulthood.
This is an investigational study. Up to 20 patients will take part in this study. All will
be enrolled at M.D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04564521 -
Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma.
|
N/A | |
Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
Withdrawn |
NCT01151748 -
Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma
|
Phase 2 | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Active, not recruiting |
NCT00360750 -
Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye
|
N/A | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Enrolling by invitation |
NCT06227962 -
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
|
||
Completed |
NCT01661400 -
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
|
Phase 1 | |
Terminated |
NCT02617862 -
PCI Imaging System in Pediatric Ophthalmology
|
N/A | |
Recruiting |
NCT02329002 -
SPT Screening in Irradiated Hereditary Retinoblastoma Survivors
|
N/A | |
Terminated |
NCT01466855 -
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
|
Early Phase 1 | |
Completed |
NCT01505569 -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
|
N/A | |
Completed |
NCT00002515 -
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT06367569 -
Evaluation of MRI of the Pineal Gland in Retinoblastoma
|
||
Completed |
NCT02193724 -
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
|
||
Completed |
NCT01884194 -
Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging
|
N/A | |
Terminated |
NCT01393769 -
Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage
|
Phase 2 | |
Completed |
NCT00006246 -
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
|
Phase 1 | |
Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 |